Live Breaking News & Updates on Clinical global impression suicidality scale

NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

RADNOR - NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar.

Massachusetts , United-states , France , French , Jonathan-javitt , Matthew-duffy , Andrew-nierenberg , Jeremy-feffer , Exchange-commission , Nasdaq , Lotus-pharmaceuticals-inc , Lotus

NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Massachusetts , United-states , Jonathan-javitt , Andrew-nierenberg , Nrx-pharmaceuticals , Alvogen-inc , Nrx-pharmaceuticals-inc , Nasdaq , Nrxp-nrx-pharmaceuticals , Lotus-pharmaceuticals-inc , Treatment-resistant-bipolar-depression-study , Lotus-pharmaceuticals

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression -January 22, 2024 at 06:49 am EST

Exceeded originally target enrollment with n=74 Last patient, last visit expected in approximately six weeks; data to follow shortly thereafterPositive.

Massachusetts , United-states , France , French , Andrew-nierenberg , Jonathan-javitt , Nasdaq , Alvogen-pharmaceuticals , Prnewswire-nrx-pharmaceuticals-inc , Nrxp-nrx-pharmaceuticals , Us-national-institutes-of-health , Nrx-pharmaceuticals-inc